Exact Sciences presented sub‑study results from NSABP B‑59 showing its Oncodetect circulating tumor DNA (ctDNA) MRD assay identified triple‑negative breast cancer patients at higher risk of distant recurrence after surgery. Investigators reported that MRD‑positive patients post‑operatively had a significantly greater risk of metastatic relapse; most MRD‑negative patients remained recurrence‑free at three years. Exact said it will submit data to MolDx as part of efforts to expand Medicare coverage for the test.